Domino's Pizza, Inc. vs BIO-TECHNE Corp — how do they compare? Domino's Pizza, Inc. trades at $357.86 (market cap $11.51B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Domino's Pizza, Inc. and BIO-TECHNE Corp are close in size by market cap, and Domino's Pizza, Inc. pays the higher dividend (2.29%). Which is the better fit depends on your goals.
| DPZ | TECH | |
|---|---|---|
Market Cap | $11.51B | $11.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $467.30 | $72.29 |
52-Week Low | $282.89 | $43.31 |
Enterprise Value | $16.47B | $11.32B |
Dividend Yield | 2.29% | 0.44% |
Signals from Pluang's Aura AI — not financial advice
DPZ trades at $350.95, down 2.09% on the day, with a bullish technical signal supported by moving averages and ADX. The company reported Q2 2026 EPS of $4.07, missing estimates, but revenue growth remains steady, with 2025 revenue at $4.94B and net income of $601.70M. Recent news highlights Domino's beta testing a new website and app with customer incentives, while institutional positions show mixed adjustments.
The outlook is mixed: analyst consensus is a Moderate Buy with a $371.67 price target, implying upside, but near-term risks include weaker ticket trends, margin pressure from rising costs, and consecutive EPS misses. High debt levels and insider selling add caution, though operational cash flow strength and brand initiatives support long-term potential.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Trailing returns across standard periods
Latest headlines on both assets
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →